Effect of a Synthetic Liver X Receptor Agonist TO901317 on Cholesterol Concentration in Goose Primary Hepatocytes

Figures & data

Figure 1. Effect of different concentrations of TO901317 on intracellular (A) and extracellular (B) cholesterol levels. The data presented are means±standard error of three independent experiments. In the same curve different letters indicate statistically significant differences between different concentrations (P<0.05), while the same letters indicate no statistically significant differences.

Figure 2. Effect of TO901317 on the mRNA expression level of PI3K, AKT, mTOR, S6K pathway by quantitative real-time PCR analysis. The data presented are means±standard error of three independent experiments. Different letters indicate statistically significant differences (P<0.05), while the same letters indicate no statistically significant differences.

Figure 3. Effect of LXR agonist TO901317 on enzyme activities of PI3K and mTOR in goose primary hepatocytes. Values are expressed as the mean±standard error of triplicate. Different letters indicate statistically significant differences (P<0.05), while the same letters indicate no statistically significant differences.

Figure 4. Effect of TO901317 on mRNA expression level of SREBP-2 and HMGR in goose primary hepatocytes by quantitative real-time PCR analysis. The data presented are means±standard error of three independent experiments. In the same genetic data, different letters indicate statistically significant differences (P<0.05), while the same letters indicate no statistically significant differences.

Figure 5. Effect of TO901317 on extracellular TG content. The data presented are means±standard error of three independent experiments. Different letters indicate statistically significant differences (P<0.05), while the same letters indicate no statistically significant differences.

Table 1. Sequence of polymerase chain reaction primers.

Gene	Primer sequence (5’-3’)	Product size (bp)
PI3K upstream	ACCCAAGCGAGGATGAGG	241
PI3K downstream	TGTTGCCCGTGTTGAATG
AKT upstream	TGCTGGATAAAGATGGAC	215
AKT downstream	CTGGTTGTAGAAAGGGAG
mTOR upstream	TCATTTGTTACTACCTCCCA	93
mTOR downstream	TTTCTAGAGCAGCTTTGCGAGCCAC
S6K upstream	CTCAACTTGCCTCCCTAC	111
S6K downstream	AACTTCTCCAGCATCTCC
SREBP-2 upstream	GGACAGATGCCAAGATGC	150
SREBP-2 downstream	GGTCAATGCCCTTCAACA
HGMR upstream	TATCCGCTTTCAGTCAAGAACAG	183
HGMR downstream	GACTTCCCTCTTCCTTCTATCCAG
18s upstream	TTGGTGGAGCGATTTGTC	129
18s downstream	ATCTCGGGTGGCTGAACG
β-actin upstream	CAACGAGCGGTTCAGGTGT	92
β-actin downstream	TGGAGTTGAAGGTGGTCTCG

PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; mTOR, mammalian target of rapamycin; SREBP-2, sterol regulatory element-binding protein 2; HGMR, 3-hydroxy-3-methylglutaryl-CoA reductase.

Table 2. Total protein and albumin accumulation of goose primary hepatocytes after TO901317 treatment.

TO901317, μmol/L	TP accumulation, g/L	ALB accumulation, g/mL
0	8.70±0.37^a	41.67±2.50^a
0.01	10.77±0.33^b	48.00±2.45^b
0.1	12.77±0.54^c	52.33±2.87^bc
1	14.20±0.49^d	56.33±1.25^c
10	16.60±0.91^e	63.00±1.63^d

TP, total protein; ALB, albumin. Different letters in the same row show significant difference among the treatment of different concentrations (P<0.05), while the same letters display no significant statistical differences.